Get the Stockscreener App
9.26
1.20%
0.11
After Hours:
9.45
0.19
+2.05%
Biohaven Ltd stock is traded at $9.26, with a volume of 1.61M.
It is up +1.20% in the last 24 hours and down -6.65% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$9.15
Open:
$9.07
24h Volume:
1.61M
Relative Volume:
0.62
Market Cap:
$1.39B
Revenue:
-
Net Income/Loss:
$-738.82M
P/E Ratio:
-1.3304
EPS:
-6.9602
Net Cash Flow:
$-610.15M
1W Performance:
+9.46%
1M Performance:
-6.65%
6M Performance:
-38.35%
1Y Performance:
-48.30%
1-Day Range:
$8.80
$9.415
1-Week Range:
$8.35
$10.16
52-Week Range:
$7.48
$24.06
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.26 | 1.38B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 110.47B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.67B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 46.53B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 43.81B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.36B | 606.42M | -1.28B | -997.58M | -6.403 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven Stock Drops 5.3% Amid Market Volatility - National Today
Biohaven (NYSE:BHVN) Trading Down 5.3%Here's Why - MarketBeat
Aug Spikes: What is the long term forecast for Biohaven Ltd stock2026 Update & Consistent Profit Trade Alerts - baoquankhu1.vn
BHVN PE Ratio & Valuation, Is BHVN Overvalued - intellectia.ai
BHVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial - Sahm
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance UK
Citigroup Forecasts Strong Price Appreciation for Biohaven (NYSE:BHVN) Stock - MarketBeat
Citi Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $17 - Moomoo
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven (NYSE:BHVN) Shares Up 10.5%Here's Why - MarketBeat
Biohaven Jumps 10.9% Amid Robust Intraday Rally—What’s Driving This Upswing? - Bitget
Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner Data - Insider Monkey
Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - MSN
Aug Final Week: Can Biohaven Ltd stock outperform in a bear market2026 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Investment Recap: Can Biohaven Ltd deliver alpha2026 Update & Accurate Intraday Trade Tips - baoquankhu1.vn
Biohaven (BHVN) completes enrollment in phase 2 obesity study of taldefgrobep alfa - MSN
Breakout Zone: Can Biohaven Ltd be recession proofDip Buying & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Biohaven (BHVN) Redefine Obesity Treatment By Targeting Lean Mass Preservation With Taldefgrobep? - Yahoo Finance
Gains Recap: How does Biohaven Ltd score in quality rankingsLayoff News & Detailed Earnings Play Alerts - baoquankhu1.vn
Market Pulse: What are analysts price targets for Biohaven Ltd2026 Volatility Report & Risk Managed Trade Strategies - baoquankhu1.vn
The Technical Signals Behind (BHVN) That Institutions Follow - Stock Traders Daily
Biohaven shares edge higher after completing enrollment in obesity drug trial - MSN
Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa - Insider Monkey
Biohaven (NYSE:BHVN) Trading 6.2% HigherHere's Why - MarketBeat
Can Biohaven (BHVN) Redefine Obesity Treatment By Prioritizing Muscle Preservation Over Pure Weight Loss? - simplywall.st
JPMorgan Chase & Co. Sells 1,236,587 Shares of Biohaven Ltd. $BHVN - marketbeat.com
Assessing Biohaven (BHVN) Valuation As Losses Persist And Price To Book Hits 25x - simplywall.st
Biohaven Shares Drop 70%, Yet a Fund’s Fresh $6 Million Investment Hints at Possible Recovery - Bitget
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Movement Recap: What is the long term forecast for Biohaven Ltd stockGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biohaven’s robust cash reserves and unique degrader strategy ignite a strong value opportunity, with crucial 2026 clinical trials approaching - Bitget
Biohaven's 2026 Pivotal Trial Countdown: Can Capital Discipline Unlock a High-Risk, High-Reward Moat? - Bitget
DAFNA Capital Management Increases Biohaven Ltd. Investment in 2025News and Statistics - IndexBox
Biohaven Ltd.: Fundamental Analysis and Financial Ratings | BHVN34 | BRBHVNBDR001 - marketscreener.com
Biohaven completes enrollment in obesity drug trial By Investing.com - Investing.com India
Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust - Stock Titan
Risk Off: What is the long term forecast for Biohaven Ltd stock2026 Market WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Biohaven Therapeutics discloses prodrugs of betahistine - BioWorld MedTech
Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa - marketscreener.com
Biohaven completes enrollment in obesity drug trial - Investing.com
Biohaven stock rises as obesity trial completes enrollment - Investing.com UK
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment - PR Newswire
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):